Fusion Pharmaceuticals (FUSN) is advancing a candidate which it acquired in February of 2023. It was acquired as an ongoing phase 2 study, known as the TATCIST trial. This is evaluating the use of FPI ...
“We believe the findings from this large-scale, real-world study add meaningfully to the substantial body of data demonstrating the clinical utility of the Decipher Prostate test,” said Michael ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results